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Available online 5 August 2016Strongyloidiasis is a life-threatening parasitic infection, especially in immunosuppressed
patients, with death often occurring within several days. The disease has a worldwide distribu-
tion and is endemic in tropical and subtropical regions. Therefore, this study was conducted to
investigate seroepidemiology of Strongyloides infection amongst immunocompromised patients
in Southwest Iran. This cross-sectional study was conducted amongst a population of
immunocompromised patients who were referred to health care or hospital referral centres
in Ahvaz, Southwest Iran. Serum samples were tested by an enzyme immunoassay for
anti-IgG Strongyloides antibody. Anti-Strongyloides stercoralis antibody was detected in 39 of
270 immunocommpromised cases, yielding a prevalence of 14.4%. No signiﬁcant differences
were indicated in terms of gender, age, or type of immunocompromised disorder with
anti-Strongyloides stercoralis antibody levels. In conclusion, our results demonstrated high
seroepidemiology of infection with this parasite in the region. Therefore, it appears immuno-
compromised patients should be tested for this infection using sensitive tests. However, current
research underscores that strongyloidosis must not be neglected, and further assessments in
high risk population are warranted.
© 2016 The Authors. Published by Elsevier Ltd on behalf ofWorld Federation of Parasitologists. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords:
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Iran1. Introduction
Strongyloidiasis is a condition caused by Strongyloides stercoralis, which may be established in humans for extended periods of
time because of its auto-infective life cycle. It may become life-threatening especially in immunocompromised hosts (Grove, 1996;
Sharifdini et al., 2014). Strongyloidiasis symptoms may vary from subclinical in acute and chronic infection to severe and fatal in
hyper infection syndrome and disseminated strongyloidiasis which, if untreated, may approach mortality rates of up to 90%
(Fernando et al., 2014; Annette et al., 2009).
The disease has worldwide distribution and is endemic to tropical and subtropical regions, such as Latin America, Asia, parts of
Africa and the southeastern United States (Genta, 1989; Steinmann et al., 2007; Scha et al., 2013; Román-sánchez et al., 2003).
Strongyloidiasis has also been reported in most parts of Iran with a higher prevalence amongst immuocompromised populations
(Zali et al., 2004; Nilforoushan et al., 2007; Meamar et al., 2007a; Froutan et al., 2008; Keiser & Nutman, 2004).eases Research Center, Health Research Institute, Ahvaz JundishapurUniversity ofMedical Sciences, Ahvaz, Iran.
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periods, which increases their risk of exposure for a longer duration, (Roseman et al., 2013; Paul et al., 2010). Parasitological diagnosis
is often time-consuming, as Strongyloides larvae in the stool are frequently absent or present in very small numbers (Afzal et al., 2001).
Recently, serological assays have been demonstrated to have reliable sensitivity and speciﬁcity for antibody detection (Salvador et al.,
2014; Bisofﬁ et al., 2014; Lindo et al., 1995). Thus, the current study was conducted to investigate the seroepidemiology of
Strongyloides infection amongst immunocompromised patients in Southwest Iran.
2. Materials and methods
2.1. Study population and sample collection
This cross-sectional study was carried out amongst a population of immunocompromised patients referred to health care or
hospital referral centres in Ahvaz, Southwest Iran. Blood samples were collected from participants from March–July 2015.
Participants suffered from leukaemia, HIV infections and different types of cancer. Demographic information including gender,
age and immunocompromised disorders were collected from hospital and medical ofﬁcial documents. All blood specimens
were centrifuged, and the serum separated and frozen at −20 °C prior to analysis for parasite-speciﬁc IgG antibodies pending
examination by an enzyme-linked immunosorbent assay (ELISA) for S. stercoralis.
2.2. Serology assay
An enzyme immunoassay for the diagnosis of human strongyloidiasis (Bordier afﬁnity products SA, Switzerland) was used. The
method was carried out according to the manufacturer's instructions. Brieﬂy, wells pre-coated and sensitised with Strongyloides
somatic larval antigens were blocked with PBS-Tween for 15 min. Wells were washed with PBS-Tween then diluted sera
[1:200] were added and incubated at 37 °C for 15′. Serum was removed and the plates were washed four times. Alkaline phos-
phatase was added, plates washed, followed by the substrate. Finally, the reaction was stopped using K3PO4. Well absorbances
were measured at 405 nm. The cutoff point was used to discriminate optimally between the sera of clinically documented stron-
gyloidiasis cases and normal human sera. The ELISA had a sensitivity of 88% and a speciﬁcity of 94%. In addition to positive and
negative controls from manufacturer using a local strongyloidiasis serum, readings were conﬁrmed by stool examination, which
was also included in each run of ELISA assay.
3. Results
The study population included 166 (61.5%) AIDS-deﬁning illness cases, 36 (13.3%) leukaemia cases and 68 (25.2%) other can-
cer cases. S. stercoralis antibody was detected in 39 immunocommpromised individuals, yielding a prevalence of 14.4%. The fre-
quency of seropositivity and immunosupresive characteristics of the study samples are shown in Table 1. As indicated, the
highest rate of antibody detection (15.7%) was found in HIV+ cases.
No signiﬁcant differences were recorded in terms of gender, age, or immunosuppressive disorder with anti-S. stercoralis
antibody levels (Table 2).
Additionally, the gender distribution of seropositivite females and males has been reported to be 16.7% and 13.3%, respectively
(Table 3).
4. Discussion
Strongyloidiasis is a parasitic infection characterised by persistent infection, dissemination and the development of potentially
fatal disease. This infection has a worldwide distribution, although no precise estimate is available. The present study shows the
seroepidemiological prevalence of S. stercoralis infection amongst immunocompromised cases in Southwest Iran to be 14.4%.
Meamar et al. conducted an investigation on strongyloidiasis in 781 HIV+/AIDS patients by the stool examination technique.
According to their results, two were determined to be infected (Meamar et al., 2007b). One report showed a 4.9% S. stercoralis
infection rate amongst rural area of Mazandaran province in Iran during 2007 (Kia et al., 2007). Additional research indicated,Table 1
Frequency of seropositivity of S. stercoralis infection amongst immunocompromised patients, Southwest Iran.
Immunocompromised cases Number IgG positive
No Frequency
HIV 166 26 15.7%
Leukaemia 36 4 11.1%
Cancer 68 9 13.2%
Total 270 39 14.4%
Table 2
Age distribution and laboratory ﬁndings of S. stercoralis infection amongst immunocompromised patients, Southwest Iran.
Age (Year) Number Frequency IgG positive
Number Frequency
0–20 8 3% 2 25%
21–40 146 54.1% 22 15%
41–60 79 29.2% 10 12.6%
N60 37 13.7% 5 13.5%
Total 270 100% 39 14.4%
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mentally disabled in southern Iran, 17.3% of the residents were found to be infected with this nematode (Shokri et al., 2012).
Our results are in agreement with other studies (Kia et al., 2007; Ashraﬁ et al., 2010; Shokri et al., 2012), regarding the high
seroprevalence of S. stercoralis infection in immunocompromised patients. Although, the prevalence rate of this parasite in Iran is
unclear, all previous studies have demonstrated that strongyloidiasis is still prevalent in some parts of the country, which are
known as endemic areas (Meamar et al., 2007b; Nesheli et al., 2011; Kia et al., 2008; Tabei et al., 2009).
Most previous studies are in agreement that the prevalence of this disease is largely underestimated (Montes et al., 2010).
These data are mostly based on surveys aimed at deﬁning the prevalence of parasitic infections, without using adequate di-
agnostic techniques for S. stercoralis. To the best of our knowledge, all the previous Iranian studies used different stool exam-
ination methods as their diagnostic, which is not sensitive, especially for chronic and asymptomatic cases (Paul et al., 2010;
Bisofﬁ et al., 2014; Bisofﬁ et al., 2013). In a stool- and sero-survey for S. stercoralis conducted in a community in the Peruvian
Amazon region, the parasite was identiﬁed in the stools of 8.7% of cases and in the sera of 72% of the cases by ELISA. Lindo
et al. reported a prevalence of 3.5% by stool examination and 24.2% by ELISA in Jamaica (Lindo et al., 1995). These results con-
ﬁrm the higher sensitivity of serological tests verses stool examinations. The ELISA has served as an excellent screening test
for strongyloidiasis (Yori et al., 2006; Zueter et al., 2014; Glinz et al., 2012). Despite the high prevalence of this infection, an
understanding of its epidemiology and seroepidemiology is limited (Requena-Me'ndez et al., 2013; Naidu et al., 2013;
Mounsey et al., 2014).
No signiﬁcant correlation was observed in terms of S. stercoralis infection and age in the current study. Some researchers
reported increasing prevalence with age, but there is no clear explanation for this ﬁnding (Lindo et al., 1995). Our data are in
agreement with most previous studies, which suggest that exposure to the parasite may not be dependent on age or gender
(Lindo et al., 1995).
The current study showed a higher rate of infection in AIDS patients, although without a statistically signiﬁcant correlation.
Although all patients were immunocompromised, this ﬁnding may be due to the low socioeconomic status of the community.
In conclusion, our results indicate high seroepidemiology of S. stercoralis infection in several risk groups in Southwest Iran. To
prevent the fatal consequences of this lethal nematode, immunocompromised patients should be tested for this parasite using
sensitive tests. Although adequate information on the prevalence of this disease is still lacking from many parts of the country,
current research suggests that S. stercoralis must not be neglected.Conﬂict of interest statement
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Gender distribution and laboratory ﬁndings of S. stercoralis infection amongst immunocompromised patients, Southwest Iran.
Gender Number Frequency IgG positive
Number Frequency
Female 90 33.3% 15 16.4%
Male 180 66.7% 24 13.3%
Total 270 100% 39 14.4%
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